NCT04777708 - BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 13, 2021

Primary Completion Date

March 13, 2023

Study Completion Date

March 13, 2023

Conditions

Advanced Hepatocellular CarcinomaBCLC Stage B Hepatocellular CarcinomaBCLC Stage C Hepatocellular CarcinomaRefractory Hepatocellular Carcinoma

Interventions

BIOLOGICAL

Nanoplexed Poly I:C BO-112

Given by intratumoral injection

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (1)

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles